Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00935493 · ClinicalTrials.gov registry record · NA
Guanfacine Treatment for Prefrontal Cognitive Dysfunction in Elderly Subjects
A NA study, sponsored by Yale University.
- Completed
- Registry status
- NA
- Development phase
- 154
- Enrollment target
NCT00935493 is a NA study that has completed, run by Yale University. The registered enrollment target is 154 participants.
The verdict
NCT00935493, a NA study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- NA
- Development phase
- 154 participants
- Enrollment target
Study Summary
This proposal aims to determine whether low does of the alpha-2A-adrenoceptor agonist guanfacine can improve deficits in prefrontally-mediated cognitive functions in healthy elderly subjects.
Interventions
- DRUG Placebo
- DRUG Guanfacine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 154 participants |
| Start Date | 2009-06 |
| Est. Completion | 2012-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00935493
The ClinicalTrials.gov registry entry for NCT00935493 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 154 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00935493 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00935493 about?
NCT00935493 is a clinical study titled "Guanfacine Treatment for Prefrontal Cognitive Dysfunction in Elderly Subjects". This proposal aims to determine whether low does of the alpha-2A-adrenoceptor agonist guanfacine can improve deficits in prefrontally-mediated cognitive functions in healthy elderly subjects.
What is the current status of trial NCT00935493?
This trial is currently completed. It is a NA study. The enrollment target is 154 participants. The study started on 2009-06. Estimated completion is 2012-08.
What interventions are being tested in trial NCT00935493?
The interventions under investigation include: Placebo (DRUG), Guanfacine (DRUG).
Who is sponsoring clinical trial NCT00935493?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.